Acne Journals

• Utilization of Topical Ruxolitinib in Dermatology This review summarizes the use of topical ruxolitinib, a JAK inhibitor, in various dermatological conditions including vitiligo, alopecia areata, atopic dermatitis, psoriasis, and more.
  Skin Therapy Letter, September 04, 2023
• Evolving Story of JAK Inhibitors for Treating Alopecia Areata Review the introduction of Janus kinase inhibitors and their application as the first-line therapeutic option for severe alopecia areata. What might be the future role of JAK inhibitors in this area?
  Skin Therapy Letter, August 03, 2023
• Testosterone for HSDD in Postmenopausal Women Review the use of transdermal testosterone for postmenopausal women with hypoactive sexual desire disorder.
  Menopause, July 20, 2023
• Mpox in Young Woman With No Epidemiologic Risk Factors An mpox diagnosis was confirmed in a young woman who presented with a facial rash with no known risk factors.
  Emerging Infectious Diseases, June 22, 2023
• Effects of Exercise and Diet on Hidradenitis Suppurativa How might exercise, weight loss, and dietary modifications be utilized as alternatives and/or adjuncts to treating hidradenitis suppurativa?
  American Journal of Clinical Dermatology, June 05, 2023
• Antibiotic Resistance in Dermatology: Combating Resistance It's crucial that dermatologists aim to combat antibiotic resistance, given the high use of antibiotics in dermatology. Review the appropriate use of antibiotics in common dermatoses in this paper.
  Skin Therapy Letter, June 01, 2023
• Pyoderma Gangrenosum in a Patient With Dubowitz Syndrome This case report describes the presentation of pyoderma gangrenosum in a patient with Dubowitz syndrome. Are these two conditions connected?
  Wounds, May 10, 2023
• Antibiotic Resistance in Dermatology: Mechanisms of Resistance This article presents a brief review of the use of antibiotics in dermatology, their mechanisms of action, and mechanisms by which antibiotic resistance develops.
  Skin Therapy Letter, May 01, 2023
• New Razor Technology Improves QoL in Pseudofolliculitis Barbae A novel razor technology designed specifically for men with pseudofolliculitis barbae was found to improve skin appearance and quality of life in men who wish to continue shaving.
  Cutis, March 08, 2023
• Acne Scars: An Update on Management Acne scars can negatively impact patients' quality of life. What is the latest evidence on effective treatment for various types of acne scarring?
  Skin Therapy Letter, March 01, 2023
• Dietary Triggers for Atopic Dermatitis in Children While food allergies are often suspected of being the cause of atopic dermatitis in children, true true food-triggered AD is surprisingly rare, as discussed in this paper.
  Cutis, March 01, 2023
• Selective TYK2 Inhibition in Chronic Plaque Psoriasis This articles focuses on oral deucravacitinib, a first-in-class selective tyrosine kinase 2 inhibitor for the treatment of moderate-to-severe chronic plaque psoriasis.
  Skin Therapy Letter, February 15, 2023
• COVID-19 and Diabetes Risk: Translating Evidence Into Action What we have learned about the potential risk of diabetes associated with COVID-19 could have important clinical and public health implications.
  Journal of Clinical Endocrinology & Metabolism, December 14, 2022
• Dermatologic Disease in Service Members and Mental Health This article explores the relationship between common dermatoses, reduced satisfaction with cutaneous body image, and increased risk for mental illness, self-harm, and suicide in military personnel.
  Cutis, October 19, 2022
• Direct-to-Consumer Teledermatology Growth This paper explores the recent and rapid expansion of direct-to-consumer teledermatology services. What are the risks and benefits of these platforms?
  Cutis, October 05, 2022
• An Update on JAK Inhibitors in Skin Disease This paper summarizes recent trials of JAK inhibitors tested in patients with moderate to severe atopic dermatitis, including topical RUX, oral abrocitinib, upadacitinib, and baricitinib.
  Cutis, September 28, 2022
• Tazarotene Lotion 0.045% for the Treatment of Acne A new formulation of the third generation synthetic retinoid tazarotene improves tolerability and epidermal penetration in the treatment of acne.
  Skin Therapy Letter, September 15, 2022
• Views and Beliefs of Vitiligo Patients in Online Forums How are online forums being utilized by patients with vitiligo? This study evaluated the online content exchanged by individuals with vitiligo to gain insight into their attitudes and concerns.
  Cutis, September 14, 2022
• JYNNEOS for PreP of Persons at Risk for Orthopoxviruses The ACIP has recommended JYNNEOS over the Vaccinia virus vaccine ACAM2000 for preexposure prophylaxis of individuals with occupational exposure to orthopoxvirus.
  Morbidity & Mortality Weekly Report, August 19, 2022
• Sarecycline: A Narrow-Spectrum Antibiotic Review the advantages of sarecycline, a novel narrow-spectrum tetracycline derivative for the treatment of moderate-to-severe acne.
  Skin Therapy Letter, July 18, 2022